Hsin-Hsu Chou1, Mei-Ju Chen2, Yuan-Yow Chiou3,4. 1. Department of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan, ROC. 2. Department of Long Term Care, Chung Hwa University of Medical Technology, Tainan, Taiwan, ROC. 3. Department of Pediatrics, National Cheng-Kung University Hospital, College of Medicine, Tainan, Taiwan, ROC. yuanyow@mail.ncku.edu.tw. 4. Institute of Clinical Medicine, National Cheng-Kung University Hospital, College of Medicine, 138 Sheng-Li Rd., Tainan, Taiwan, ROC. yuanyow@mail.ncku.edu.tw.
Abstract
BACKGROUND: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). METHODS: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. RESULTS: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. CONCLUSION: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
BACKGROUND: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). METHODS: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. RESULTS: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. CONCLUSION: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.
Authors: M Zeher; A Doria; J Lan; G Aroca; D Jayne; I Boletis; F Hiepe; H Prestele; P Bernhardt; Z Amoura Journal: Lupus Date: 2011-10-05 Impact factor: 2.911
Authors: Michael Walsh; Matthew James; David Jayne; Marcello Tonelli; Braden J Manns; Brenda R Hemmelgarn Journal: Clin J Am Soc Nephrol Date: 2007-08-08 Impact factor: 8.237
Authors: Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera Journal: Ann Rheum Dis Date: 2010-09-10 Impact factor: 19.103
Authors: Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas Journal: RMD Open Date: 2020-07